相关实验视频
Updated: May 2, 2026

10:24
Xenopus laevis as a Model to Identify Translation Impairment
Published on: September 27, 2015
11.0K
第1组mGluR刺激挽救了神经元中APOE4介导的翻译缺陷
Bindushree K Radhakrishna1,2, Ahamed P Kaladiyil1, Anushree Chakraborty3
1Centre for Brain Research, Indian Institute of Science, Bangalore, India.
Life science alliance
|November 11, 2025
概括
阿波利波蛋白E4 (APOE4) 损害神经元蛋白质合成,这是阿尔茨海默病的关键因素. 第1组甲基酸盐受体 (mGluRs) 可以通过mTOR途径拯救这种损伤,这表明APOE4载体是治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- Apolipoprotein E4 (APOE4) 是阿尔茨海默病 (AD) 的一个主要遗传风险因素.
- APOE4 损害神经元信号传递和蛋白质合成,导致神经退行和突触功能障碍.
- 第1组甲基酸盐受体 (mGluRs) 对突触可塑性和蛋白质合成至关重要.
研究的目的:
- 为了研究APOE4对神经元蛋白质合成对mGluR刺激的反应的影响.
- 为了确定基底的分子机制mGluR介导的救援APOE4诱导的赤字.
- 探索mGluR激活在APOE4相关认知障碍中的治疗潜力.
主要方法:
- 来自Sprague-Dawley大鼠胚胎的原发皮质神经元被用APOE4.4治疗.
- 测量了神经元蛋白质合成和突触活性.
- 使用拉巴胺素治疗,评估了哺乳动物目标拉巴胺素 (mTOR) 途径的作用.
- 使用mGluR刺激来检查救援效应.
主要成果:
- 暴露在APOE4中抑制了蛋白质合成,并降低了神经元中的突触活性.
- mGluR刺激挽救了由APOE4.4引起的蛋白质合成抑制和突触活动减少.
- 救援效应取决于RPS6的酸化,这是mTOR通路的下游目标.
- 这种mGluR介导的救援独立于APOE4诱导的信号缺陷.
结论:
- 1组mGluR刺激可以有效地抵消APOE4引起的神经元蛋白质合成和突触活动的损害.
- mTORC1通路在调解这种救援效果方面发挥着至关重要的作用.
- 激活mGluR是一种潜在的治疗策略,可以减轻APOE4对阿尔茨海默病中的突触可塑性和认知的有害影响.
相关概念视频
Leaky Scanning
4.5K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
4.5K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21

